Peptide and Anticoagulant Drugs Market Research Report – Forecast to 2027

Peptide and Anticoagulant Drugs Market Research Report, by Type (Antibiotic, ACE Inhibitor, and Glatiramer Acetate), Application (Diabetes and Cancer) End Users (Hospital and Clinics, Research Centers, Diagnostic Center) – Forecast Till 2027

ID: MRFR/Pharma/4926-HCR | | Region: Global | 100 pages

Peptide And Anticoagulant Drugs Market Scenario


Anticoagulants are referred to as blood thinners. It is a chemical substance that prevents or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals, it helps to keep the bitten area unclotted long enough for the animal to obtain some blood. Anticoagulants are related to and thrombolytic drugs and antiplatelet drugs by manipulating the various pathways of blood coagulation which inhibit platelet aggregation. These drugs are majorly used for deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. Peptides are long chain amino acids. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of peptide and anticoagulant drugs market. Also, an increase in the rate of Diabetes and Cancer promotes the growth of the market. According, to WHO in 2017 diabetes patients has risen from 108 million in 1980 to 422 million in 2014. Global prevalence of diabetes in adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014. Also predicted that breast cancer rates are highest in non-Hispanic white women, breast cancer death rates are highest in African American women which increase the growth of peptide and anticoagulant drugs market in the forecast period.  However, the higher price of NOACs and lack of antidots for NOACs impede the market growth.


Segmentation


The peptide and anticoagulant drugs Market is segmented on the basis of type, application and end users. The market by type is hormonal, antibiotic, ACE inhibitor antifungal, other peptide drugs, and anticoagulants. Hormonal is sub-segmented into categorized into insulin teriparatide and leuprolide acetate. Antibiotic is categorized into eptifibatide and warfarin. On the basis of anticoagulants, the market is sub-segmented into enoxaparin sodium and heparin sodium. and on the basis of application, the market is sub-segmented into diabetes, cancer, infectious diseases, cancer, osteoporosis, cardiology, gynecology, other. On the basis of end users, the market is segmented into hospitals, research centers, and diagnostic centers.


On the basis of region, the peptide and anticoagulant drugs Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. According to the cancer organization in 2017, it was found that 63,410 new cases of breast carcinoma in situ, 252,710 new cases of invasive breast cancer, and 40,610 breast cancer deaths.


 The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players for peptide and anticoagulant drugs market


Some of the key players in the global peptide drugs market are Abbott Laboratories (U.S.), Cadila Pharmaceuticals (India), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).


Regional Market Summary  


Global Peptide and Anticoagulant Drugs Market Share (%), by Region, 2017


Peptide and Anticoagulant Drugs Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the peptide and anticoagulant drugs Market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. According, to WHO in it was estimated that diabetes was the cause of 1.6 million deaths. Most of all deaths related to high blood glucose occur before the age of 70 years. WHO also projected that diabetes will be the seventh leading cause of death in 2030 which can be the major leading factor in the growth of market in this region.


Europe stood second largest in the peptide and anticoagulant drugs market owing to the increasing use of tobacco. According to the Cancer Research UK, 359,960 cases of cancer were found in 2015. Also, 35,620 deaths caused due to lung cancer in this region due to change in lifestyle which can enhance the growth of market.


Asia-Pacific was projected to be the fastest growing region for the peptide and anticoagulant drugs Market in 2017. The market is expected to witness growth owing to the rising prevalence of cancer, changing lifestyle, and increasing tobacco use within the population. The international diabetes federation estimated 72,946,400 cases of diabetes in India in 2017. Such a high incidence of diabetes cases favors the market growth in this region.


The Middle East and Africa holds the least share in the peptide and anticoagulant drugs Market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Intended Audience



  • Pharmaceutical companies

  • Peptide and anticoagulant drugs manufacturers

  • Peptide and anticoagulant drugs marketing players

  • Peptide and anticoagulant drugs distributors

  • Various research and consulting companies


Market Segmentation


Market Of Peptide and Anticoagulant Drugs, by Type



  • Hormonal

  • Insulin

  • Teriparatide

  • Leuprolide Acetate

  • Antibiotic

  • Eptifibatide

  • Warfarin



  • ACE Inhibitor

  • Antifungal

  • Other Peptide Drugs

  • Anticoagulants

  • Enoxaparin Sodium

  • Heparin Sodium

  • Others


Market Of Peptide And Anticoagulant Drugs, by Application



  • Diabetes

  • Infectious Diseases

  • Cancer

  • Osteoporosis

  • Cardiology

  • Gynecology

  • Others


Market Of Peptide And Anticoagulant Drugs, by End-Users



  •  Introduction

  •  Hospitals and clinics

  • Research Centers

  • Diagnostic Centers


Market Of Peptide And Anticoagulant Drugs, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The high price of NOACs and lack of antidotes can prevent peptide & anticoagulants drug market growth.

The study includes segments like antibiotics, hormonal, other peptide drugs, ACE inhibitor antifungal, and anticoagulants.

The segments are enoxaparin sodium and heparin sodium for discussion.

North America would be well-placed to achieve the highest valuation for peptide & anticoagulants drugs market.

The fastest-growing region for peptide & anticoagulants drugs market would be the Asia Pacific.